1. 1. On or before February 1 of each year, the Authority shall compile:

   1. (a) A list of prescription drugs that the Authority determines to be essential for treating diabetes in this State and the wholesale acquisition cost of each such drug on the list. The list must include, without limitation, all forms of insulin and biguanides marketed for sale in this State.

   2. (b) A list of prescription drugs described in paragraph (a) that have been subject to an increase in the wholesale acquisition cost of a percentage equal to or greater than:

      1. (1) The percentage increase in the Consumer Price Index, Medical Care Component during the immediately preceding calendar year; or
      2. (2) Twice the percentage increase in the Consumer Price Index, Medical Care Component during the immediately preceding 2 calendar years.

   3. (c) A list of prescription drugs that:

      1. (1) Except as otherwise provided in subsection 2, have a wholesale acquisition cost exceeding $40 for a course of therapy; or

      2. (2) Have been subject to an increase in the wholesale acquisition cost of a percentage equal to or greater than:

         1. (I) Ten percent during the immediately preceding calendar year; or
         2. (II) Twenty percent during the immediately preceding 2 calendar years.
2. 2. To the extent that money is available to include such drugs in the reporting conducted pursuant to NRS 439B.635 to 439B.645, inclusive, the Authority may include on the list compiled pursuant to paragraph (c) of subsection 1 prescription drugs that meet the criteria prescribed in subparagraph (2) of that paragraph but have a wholesale acquisition cost that does not exceed $40 for a course of therapy. The Authority shall prioritize for inclusion the prescription drugs for which the benefit to the public of reporting pursuant to NRS 439B.635 to 439B.645, inclusive, would be the greatest, as determined by the Authority.

3. 3. As used in this section, “course of therapy” means:

   1. (a) Except as otherwise provided in paragraph (b), the recommended daily dosage of a prescription drug, as set forth on the label for the prescription drug approved by the United States Food and Drug Administration, for 30 days.
   2. (b) If the normal course of treatment using a prescription drug is less than 30 days, the recommended daily dosage of a prescription drug, as set forth on the label for the prescription drug approved by the United States Food and Drug Administration, for the duration of the recommended course of treatment.

(Added to NRS by 2017, 4297; A 2019, 1465; 2021, 3723; 2025, 3705)